513 related articles for article (PubMed ID: 22465543)
1. Organic nanocarriers for cancer drug delivery.
López-Dávila V; Seifalian AM; Loizidou M
Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
4. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
[TBL] [Abstract][Full Text] [Related]
5. Nanocarriers for cancer-targeted drug delivery.
Kumari P; Ghosh B; Biswas S
J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
[TBL] [Abstract][Full Text] [Related]
6. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
7. Advances in polymeric micelles for drug delivery and tumor targeting.
Kedar U; Phutane P; Shidhaye S; Kadam V
Nanomedicine; 2010 Dec; 6(6):714-29. PubMed ID: 20542144
[TBL] [Abstract][Full Text] [Related]
8. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting.
Sawant RR; Torchilin VP
Mol Membr Biol; 2010 Oct; 27(7):232-46. PubMed ID: 20929339
[TBL] [Abstract][Full Text] [Related]
9. Active targeting strategies for anticancer drug nanocarriers.
Basile L; Pignatello R; Passirani C
Curr Drug Deliv; 2012 May; 9(3):255-68. PubMed ID: 22452402
[TBL] [Abstract][Full Text] [Related]
10. Liposomal nanomedicines.
Fenske DB; Cullis PR
Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
[TBL] [Abstract][Full Text] [Related]
11. Improvement of drug safety by the use of lipid-based nanocarriers.
Lim SB; Banerjee A; Önyüksel H
J Control Release; 2012 Oct; 163(1):34-45. PubMed ID: 22698939
[TBL] [Abstract][Full Text] [Related]
12. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.
Agarwal A; Mackey MA; El-Sayed MA; Bellamkonda RV
ACS Nano; 2011 Jun; 5(6):4919-26. PubMed ID: 21591812
[TBL] [Abstract][Full Text] [Related]
13. Role of nanocarrier systems in cancer nanotherapy.
Mozafari MR; Pardakhty A; Azarmi S; Jazayeri JA; Nokhodchi A; Omri A
J Liposome Res; 2009; 19(4):310-21. PubMed ID: 19863166
[TBL] [Abstract][Full Text] [Related]
14. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
15. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes.
Gaucher G; Marchessault RH; Leroux JC
J Control Release; 2010 Apr; 143(1):2-12. PubMed ID: 19925835
[TBL] [Abstract][Full Text] [Related]
16. Stimuli-sensitive nanopreparations for combination cancer therapy.
Jhaveri A; Deshpande P; Torchilin V
J Control Release; 2014 Sep; 190():352-70. PubMed ID: 24818767
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
Sultana S; Khan MR; Kumar M; Kumar S; Ali M
J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
[TBL] [Abstract][Full Text] [Related]
18. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
[TBL] [Abstract][Full Text] [Related]
19. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.
Cabral H; Nishiyama N; Kataoka K
J Control Release; 2007 Aug; 121(3):146-55. PubMed ID: 17628162
[TBL] [Abstract][Full Text] [Related]
20. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
